|
TRIPTORELIN ACETATE |
| Synonyms. Triptorelin acetate; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L- leucyl-L- arginyl-L -prolylglycinamide; (6-D-Tryptophan)luteinizing hormone-releasing hormone; (D-Trp6)-GnRH; D-Tryptophan-LH-RH; Decapeptyl; Dekapeptil; Diferelin; Diphereline; Triptorelin; Triptorelina; Triptoreline; Triptorelinum; Trelstar; 6-D-Tryptophan-LH-RH; 6-D-Tryptophanluteinizing Hormone-releasing Factor; Detryptoreline; D-TRP-6-LHRH; |
|
|
| PRODUCT IDENTIFICATION | |
|
CAS RN |
57773-63-4(parent), 140194-24-7 (acetate), 124508-66-3 (pamoate) |
|
EINECS RN |
|
|
FORMULA |
C64H82N18O13 |
|
MOLE WEIGHT |
1311.45 |
|
H.S CODE |
2933.99.7900 |
|
SMILES |
c12c(CC(NC(=O)C(Cc3ccc(cc3)O)NC(=O)C(NC(= O)C(Cc3c4c ([nH]c3 )cccc4)NC(=O)C(Cc3c[nH]cn3)NC(=O)C3NC(= O)CC3)CO)C(=O )NC(C( =O)NC(C(=O)N3C(CCC3)C(=O)NCC(=O)N) CCCNC( =N)N)CC(C)C)c[nH ]c1cccc2.CC(=O)O |
|
CLASSIFICATION |
Polypeptide, Antineoplastic, Antineoplastic, Contraceptive, Luteolytic |
|
EXTRA NOTES |
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6. |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES | |
|
PHYSICAL STATE. |
white powder |
|
MELTING POINT |
|
|
BOILING POINT |
|
|
DENSITY |
|
|
SOLUBILITY IN WATER |
Soluble (soluble in 1% acetic acid) |
| SOLVENT SOLUBILITY | |
|
VAPOR DENSITY |
|
|
log P(octanol-water) |
|
|
VAPOR PRESSURE |
|
|
AUTOIGNITION TEMP |
|
| pH |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions. |
|
INCOMPATIBLE MATERIALS |
Strong acids, Strong bases |
| POLYMERIZATION |
Has not been reported |
|
NFPA RATINGS |
Health: 2,Flammability:0, Reactivity: 0 |
|
|
| EXTERNAL LINKS & GENERAL DESCRIPTION | |
|
Triptorelin: A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men (http://www.cancer.gov/) Triptorelin is a form of hormone therapy called an LHRH (luteinizing hormonereleasing hormone) agonist. There are two brands of the same drug, which are called Decapeptyl SR and Gonapeptyl Depot. Triptorelin slows down the growth of prostate cancer cells by blocking a message from the brain telling the testicles to produce testosterone. Most prostate cancer cells need testosterone to grow and spread. (http://www.prostate-cancer.org.uk/) Leuprorelin and triptorelin, two Gn-RH analogues, are the first drugs to be licensed in France for preoperative treatment of uterine leiomyoma associated with anaemia, when a reduction in the size of the leiomyoma is necessary to facilitate or modify the surgical technique. A solid-blind placebo-controlled trial of leuprorelin in nearly 300 anaemic women showed no advantage in terms of the need for non autologous transfusion. Three solid-blind placebo-controlled trials have shown that leuprorelin reduces the volume of uterine leiomyomas, but whether or not this facilitates or modifies the surgical technique is not known. An unblinded trial versus lynestrenol in non anaemic women showed a superior effect of leuprorelin on the size of the leiomyoma, but again there were no data on a possible effect on the choice of surgical technique. In the absence of comparative solid-blind trials, the observed effects of triptorelin on the choice of surgical technique are uninterpretable. The adverse effects of leuprorelin are mainly linked to its hormone effect, i.e. flushing, headache, vaginitis and vaginal dryness. There are no recent reviews of the adverse effects of triptorelin in this setting. In practice, for anaemic women with leiomyomas requiring surgery, there is no proof that leuprorelin and triptorelin have any tangible clinical advantages.(http://www.medscape.com/)Triptorelin is a synthetic analogue of gonadorelin (natural GnRH decapeptide) with amino acid (D-tryptophan) substitution in position 6 to inhibit rapid degradation for long activity. Used as triptorelin pamoate or acetate form, triptorelin is used as an antineoplastic in the palliative treatment of prostatic carcinoma, administered intramuscularly. Other analogues with two substituents in position 6 and 10 include Buserelin, Deslorelin. Goserelin, Histrelin, Leuprolide, Nafarelin,
|
|
|
| SALES SPECIFICATION |
|
|
APPEARANCE |
white to slightly yellowish powder |
| IDENTIFICATION |
pass (HPLC) |
|
PURITY |
98.0% min |
| AMINO ACID | 1.0 ± 10% (each theoretical Composition) |
|
RELATED SUBSTANCES |
2.0% max (total impurity), 1.0% max (Individual impurity) |
| PEPTIDE CONTENT |
80.0%
min (N determination)
|
| ACETATE CONTENT |
15.0% max |
| WATER CONTENT | 5.0% max |
| OPTICAL ROTATION |
-65.0° ~ -75.0°(c=0.5, 95% HAc) |
| BACTERIAL ENDOTOXINS | 5EU/mg max |
|
|
| TRANSPORT & REGULATORY INFORMATION | |
|
UN NO. |
Not known |
| HAZARD CLASS |
|
| PACKING GROUP | |
|
|
| SAFETY INFORMATION |
|
|
HAZARD OVERVIEW |
Avoid contact and inhalation. May causes eye irritation. May causes skin irritation. May cause gastrointestinal irritation. May causes respiratory tract irritation |
| HAZARD CODES |
|
|
RISK PHRASES |
|
|
SAFETY PHRASES |
22-24/25 |
|
|
| PACKING |
|
|